Compare AbbVie Inc (ABBV) vs ARK Innovation ETF (ARKK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs ARK Innovation ETF — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while ARK Innovation ETF trades at $80.51. The key difference: AbbVie Inc pays a 2.79% dividend while ARK Innovation ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | ARKK | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | — |
52-Week High | $263.58 | $92.50 |
52-Week Low | $197.38 | $63.52 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
ARK Innovation ETF (ARKK) trades at $79.43, up 4.89% today with strong technical momentum as moving averages signal bullish alignment. The ETF faces mixed sentiment with recent Seeking Alpha articles highlighting concentration risks in SpaceX and Tesla holdings while Cathie Wood continues aggressive AI stock purchases. Technical indicators show RSI at overbought levels near 82, suggesting potential near-term consolidation despite the bullish trend.
Outlook remains polarized between innovation optimism and valuation concerns. The fund's heavy exposure to speculative tech names offers growth potential but carries significant volatility risk. Recent underperformance versus broad market indices and high fee structure present headwinds, while continued institutional interest in disruptive technologies provides long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →
